Lamotrigine Augmentation in Treatment-Resistant Pediatric Obsessive-Compulsive Disorder with a 16 Month Follow-up

Abramowitz JS , Taylor S , McKay D : Obsessive-compulsive disorder. Lancet, 374:491–499, 2009.

Ackerman DL , Greenland S , Bystritsky A : Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol, 18:185–192, 1998.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.

American Psychiatric Association: DSM-5 Task Force. In: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2013.

Apter A , Fallon TJ Jr , King RA , Ratzoni G , Zohar AH , Binder M , Weizman A , Leckman JF , Pauls DL , Kron S , Cohen DJ : Obsessive-compulsive characteristics: From symptoms to syndrome. J Am Acad Child Adolesc Psychiatry, 35:907–912, 1996.

Arrojo–Romero M , Tajes Alonso M , de Leon J : Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry, 2013:612459, 2013.

Bisol LW , Lara DR : Improvement of obsessive-compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder. Pharmacopsychiatry, 42:37–39, 2009.

Bloch MH , Landeros–Weisenberger A , Kelmendi B , Coric V , Bracken MB , Leckman JF : A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry, 11:622–632, 2006.

Bruno A , Mico U , Pandolfo G , Mallamace D , Abenavoli E , Di Nardo F , D'Arrigo C , Spina E , Zoccali RA , Muscatello MR : Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. J Psychopharmacol, 26:1456–1462, 2012.

Burstein AH : Lamotrigine. Pharmacotherapy, 15:129–143, 1995.

Catapano F , Perris F , Masella M , Rossano F , Cigliano M , Magliano L , Maj M : Obsessive-compulsive disorder: A 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. J Psychiatr Res, 40:502–510, 2006.

Coric V , Taskiran S , Pittenger C , Wasylink S , Mathalon DH , Valentine G , Saksa J , Wu YT , Gueorguieva R , Sanacora G , Malison RT , Krystal JH : Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry, 58:424–428, 2005.

Goodman WK : Obsessive-compulsive disorder: Diagnosis and treatment. J Clin Psychiatry, 60 Suppl 18:27–32, 1999.

Grant P , Lougee L , Hirschtritt M , Swedo SE : An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol, 17:761–767, 2007.

Haghighi M , Jahangard L , Mohammad–Beigi H , Bajoghli H , Hafezian H , Rahimi A , Afshar H , Holsboer–Trachsler E , Brand S : In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl), 228:633–640, 2013.

Hurley SC : Lamotrigine update and its use in mood disorders. Ann Pharmacother, 36:860–873, 2002.

Kessler RC , Berglund P , Demler O , Jin R , Merikangas KR , Walters EE : Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:593–602, 2005.

Kumar TC , Khanna S : Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry, 34:527–528, 2000.

Lafleur DL , Pittenger C , Kelmendi B , Gardner T , Wasylink S , Malison RT , Sanacora G , Krystal J H , Coric V : N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl), 184:254–256, 2006.

Leonard HL : New developments in the treatment of obsessive–compulsive disorder. J Clin Psychiatry, 58 Suppl 14:39–45, 1997.

Mowla A , Khajeian AM , Sahraian A , Chohedri AH , Kashkoli F : Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr, 15: 613–617, 2010.

National Institute for Health and Clinical Excellence. NICE Obsessive-compulsive disorder: quick reference guide. 2005. Available at guidence.nice.org.uk/CG31/QuickRefGuide/pdf/English.

Pallanti S , Bernardi S , Antonini S , Singh N , Hollander E : Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: A preliminary, single-blind, prospective study. CNS Drugs, 23:1047–1055, 2009.

Pallanti S , Quercioli L : Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry, 30:400–412, 2006.

Pittenger C , Bloch MH , Williams K : Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther, 132:314–332, 2011.

Poyurovsky M , Glick I , Koran LM : Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol, 24:861–866, 2010.

Pressler RM , Binnie CD , Coleshill SG , Chorley GA , Robinson RO : Effect of lamotrigine on cognition in children with epilepsy. Neurology, 66:1495–1499, 2006.

Reid JG , Gitlin MJ , Altshuler LL : Lamotrigine in psychiatric disorders. J Clin Psychiatry, 74:675–684, 2013.

Seo HJ , Chiesa A , Lee SJ , Patkar AA , Han C , Masand PS , Serretti A , Pae CU : Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol, 34:39–47, 2011.

Serata D , Kotzalidis GD , Rapinesi C , Janiri D , Di Pietro S , Callovini G , Piacentino D , Gasperoni C , Brugnoli R , Ferri VR , Girardi N , Tatarelli R , Ferracuti S , Angeletti G , Girardi P , Del Casale A : Are 5-HT antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol, 30:70–84, 2015.

Simpson HB , Foa EB , Liebowitz MR , Ledley DR , Huppert JD , Cahill S , Vermes D , Schmidt AB , Hembree E , Franklin M , Campeas R , Hahn CG , Petkova E : A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry, 165:621–630, 2008.

Soltani F , Sayyah M , Feizy F , Malayeri A , Siahpoosh A , Motlagh I : A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol, 25:509–513, 2010.

Stein DJ , Koen N , Fineberg N , Fontenelle LF , Matsunaga H , Osser D , Simpson HB : A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep, 14:211–219, 2012.

Ting JT , Feng G : Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics, 2:62–75, 2008.

Uzun O : Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: A case report. J Psychopharmacol, 24:425–427, 2010.

van der Loos M , Calabrese J , Nolen W , Muzina D : Pharmacological profile and clinical utility of lamotrigine in mood disorders. In: Bipolar Psychopharmacotherapy: Caring for the Patient, 2nd ed. Edited by Akiskal H. , and Tohen M. . Chichester: Wiley-Blackwell; 2011; pp. 45–60.

Walsh KH , McDougle CJ : Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opin Pharmacother, 5:2059–2067, 2004.

Wu K , Hanna GL , Rosenberg DR , Arnold PD : The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav, 100:726–735, 2012.